Asthma and allergic diseases are highly prevalent among pregnant women, and inadequate control is associated with increased risks of adverse maternal and fetal outcomes. Importantly, concerns about drug safety often result in therapeutic hesitation and undertreatment. This review summarizes the latest evidence on the pharmacological and safety considerations of asthma and allergy therapies during pregnancy. First, we describe the physiological changes of pregnancy, including alterations in the respiratory, cardiovascular, gastrointestinal, and renal systems, that significantly affect drug pharmacokinetics and pharmacodynamics. Second, we assess the safety profiles of commonly used therapies, including inhaled corticosteroids, long-acting β-agonists, long-acting muscarinic antagonists, systemic corticosteroids, and biologic agents. Finally, we highlight the importance of self-management, asthma action plans, multidisciplinary coordination, and shared decision-making. All of these approaches improve adherence, disease control, and outcomes in pregnant women with asthma.
INTRODUCTION:Both percutaneous left atrial appendage occlusion (LAAO) and nonvitamin K antagonist oral anticoagulants (NOACs) are noninferior to warfarin for stroke prevention in high-risk patients with atrial fibrillation (AF). However, there is limited data comparing LAAO with NOACs. The CATALYST trial compares a dual-seal LAAO device (Amplatzer™ Amulet™) to NOACs in AF patients indicated for thromboprophylaxis. METHOD:CATALYST is a prospective, multicenter, randomized controlled, open-label trial with an adaptive statistical design. Up to 2,650 AF patients with CHA2DS2-VASc score ≥2 (men) or ≥3 (women) will be randomly assigned to LAAO or NOAC at 123 global sites. Patients randomized to NOACs take the appropriate labeled dose with compliance monitored at each visit, while LAAO patients receive dual antiplatelet therapy followed by aspirin monotherapy for ≥12 months postimplant. Patients are followed through 5 years, with postimplant cardiac imaging at 3- and 12-months. There are three co-primary endpoints: (1) ischemic stroke, systemic embolism, or cardiovascular death through 2 years, tested for noninferiority; (2) major or clinically relevant nonmajor bleeding through 2 years, tested for superiority; and (3) ischemic stroke or systemic embolism through 3 years, tested for noninferiority. The following secondary endpoints will be tested if the primary endpoints are met: (1) all-bleeding, tested for noninferiority; (2) followed by testing for superiority; (3) disabling or fatal strokes, tested for superiority; all through 2 years. CONCLUSIONS:CATALYST is evaluating the safety and effectiveness of a dual seal LAAO device compared to NOACs in patients with AF at increased risk of stroke. CLINICAL TRIAL REGISTRATION:URL https://clinicaltrials.gov; Unique Identifier NCT04226547.
Esophagogastroduodenoscopy is essential to evaluate symptoms of suspected eosinophilic esophagitis (EoE), assess endoscopic findings, obtain biopsy specimens for histopathologic evaluation, perform esophageal dilation, confirm the diagnosis, and monitor the condition. The American Society for Gastrointestinal Endoscopy (ASGE) previously provided consensus recommendations on the approach to endoscopy in EoE across topics of endoscopic diagnosis, endoscopic grading, and esophageal dilation. Because additional areas of endoscopy still required guidance, we performed an independent modified Delphi process focusing on pediatric considerations, disease assessment, and disease monitoring. A core group of EoE experts reviewed published guidelines and developed a set of patient-centered recommendation statements informed by literature review. A multidisciplinary group of adult and pediatric international EoE experts then voted on the statements over 2 Delphi rounds. All statements with 80% agreement were accepted for inclusion. This process yielded 28 consensus statements. Pediatric-specific statements covered when to suspect EoE and perform endoscopy, how to grade endoscopic severity, and when and how to perform esophageal dilation in children. Statements across all age ranges addressed the role of less-invasive monitoring, performing diagnostic endoscopy off treatment, the need to consider symptoms, endoscopic features, and histologic findings when assessing disease activity, treatment-based monitoring intervals, and the approach to esophageal biopsies during monitoring. Coupled with the original consensus work, we provide a comprehensive endoscopic approach to EoE as well as practical guidance for procedure-related aspects in the field to facilitate high-quality endoscopic care to patients with EoE. (Gastrointest Endosc 2026;103:396-417.)
Abstract Background Cardiovascular disease risk is associated with plaque volume. However, women generally have lower plaque volume, more non-calcified plaque, and smaller coronary arteries compared to men and unclear how this impacts clinical outcomes. Artificial intelligence quantitative coronary CT angiography (AI QCT) provides automated plaque characteristics which can be evaluated for its relationship with clinical outcomes in women and men. Purpose To evaluate sex specific differences in AI QCT (CLEERLY) plaque characteristics and clinical outcomes. Methods Adults clinically referred for coronary CT angiography from 2017-2018 were using cardiac-gated CT. Patients with prior revascularization were excluded. 461 adults met inclusion criteria. AI QCT quantified total plaque volume, calcified plaque, non-calcified plaque, low density plaque, vessel volume, lumen volume, lumen area, vessel length, plaque diffuseness, diameter/area stenosis. Percent atheroma volume was calculated as plaque volume divided by vessel volume multiplied by 100. Coronary calcium scores were extracted from anonymized reports using natural language processing with manual audit. The primary endpoint was first hospitalization for non-fatal acute coronary syndrome, non-fatal stroke, new atrial fibrillation, new heart failure, delayed revascularization (greater than 90 days), or cardiovascular death. Cox proportional hazard ratios were calculated for the full cohort and by sex. Results A total of 461 adults were included, 179 women and 282 men. Mean age for women was 67 years and for men was 64 years. Men had higher body mass index and incidence of smoking exposure. Hypertension, diabetes mellitus, and LDL cholesterol were similar across sex. Median follow up was 7.3 years in women and 7.6 years in men. All plaque characteristics differed between men and women (p < 0.01) (Figure 1). There were 119 primary endpoint events: 41 in women and 78 in men. 15 were lost to follow up or had no events. Women had fewer total events but both men (N = 33) and women (N = 16) had the highest non-fatal acute coronary syndrome events. Event free survival was higher in women. Plaque volume, percent atheroma volume, plaque diffuseness, and stenosis were associated with the primary endpoint. For both men and women, stenosis area and diameter were significant predictors. However, in men, low density plaque was the most significant predictor while in women plaque diffuseness was more associated with events compared to men (HR 1.74 vs 1.48, p < 0.01) (Figure 2). Conclusions Sex differences in plaque characteristics were present across the cohort. While women had lower plaque volume, there was a stronger association between plaque diffusiveness and clinical outcomes compared to men. Men with low density plaque were more likely to have clinical outcomes. These observations show that different plaque characteristics drive clinical outcomes in women and men.Figure 1.Plaque characteristics by sexFor image description, please refer to the figure legend and surrounding text. Table 1.Hazard Ratios by SexFor image description, please refer to the figure legend and surrounding text.